Comparing demographics data between intubation and non-progression groups
| Demographics | Intubation (n=37) | Non-intubation (n=67) | P value |
| Age (years, mean±SD) | 63.9 (±11.67) | 58.9 (±14.17) | 0.06 |
| Sex (F) n (%) | 16 (43.24 %) | 33 (49.25 %) | 0.55 |
| BMI kg/m2 (mean±SD) | 31.0 (±6.74) | 32.8 (±8.33) | 0.27 |
| Comorbidities n (%) | |||
| Diabetes | 12 (33.33%) | 23 (35.38%) | 0.84 |
| Hypertension | 21 (56.76%) | 25 (38.46%) | 0.07 |
| Lung Dx | 14 (38.89%) | 17 (26.15%) | 0.18 |
| Heart Dx | 10 (27.03%) | 13 (20.00%) | 0.41 |
| CKD | 7 (21.21%) | 8 (13.56%) | 0.34 |
| Chronic haemodialysis | 4 (12.12%) | 5 (8.47%) | 0.57 |
| Race | |||
| African-American | 18 (48.65%) | 35 (52.24%) | 0.192 |
| Hispanic | 8 (21.62%) | 15 (22.62%) | |
| Caucasian | 6 (16.22%) | 3 (4.48%) | |
| Other | 0 | 4 (5.97%) | |
| Unknown | 5 (13.51%) | 10 (14.93%) | |
| Smoking* n (%) | |||
| No | 15 (41.67%) | 36 (57.14%) | 0.19 |
| Yes | 18 (50.00%) | 25 (39.68%) | |
| Initial vitals | |||
| HR (mean±SD) | 97.32 (±21.98) | 98.3 (±19.24) | 0.80 |
| RR (mean±SD) | 21.49 (±6.11) | 22.3 (±5.09) | 0.45 |
| Temperature (mean±SD) | 99.2 (±2.54) | 99.6 (±1.95) | 0.36 |
| Pulse oximetry (mean±SD) | 89.2 (±12.30) | 90.4 (±8.67) | 0.58 |
| Laboratory abnormalities | |||
| Mean (±SD) | |||
| Ferritin (ng/mL) | 1078.2 (±1720.37) | 1290.5 (±3236.69) | 0.59 |
| CRP (mg/dL) | 12.51 (±10.02) | 11.35 (±7.38) | 0.90 |
| LDH (U/L) | 444.51 (±322.57) | 463.4 (±244.33) | 0.58 |
| D-dimer (ng/mL) | 9241.76 (±24519.18) | 3604.36 (±10938.11) | 0.36 |
| Fibrinogen (mg/dL) | 430.9 (±205.05) | 523.64 (±153.66) | 0.009 |
| Abs Lymph Ct (K/mm3)* | 1.05 (±0.43) | 1.00 (±0.50) | 0.39 |
| IL-6 (pg/mL) | 130.9 (±210.15) | 42.6 (±48.07) | 0.12 |
| AST (U/L) | 69.2 (±112.06) | 48.6 (±32.45) | 0.90 |
| ALT (U/L) | 39.78 (±43.54) | 37.85 (±22.89) | 0.51 |
| Platelets (K/mm3) | 215.2 (±115.74) | 225.5 (±101.02) | 0.60 |
| Triglycerides (mg/dL) | 293.96 (±454.58) | 145.26 (±75.86) | 0.52 |
| BUN (mg/dL) | 31.95 (±21.86) | 26.32 (±25.24) | 0.08 |
| Creatinine (mg/dL) | 2.88 (±3.58) | 2.46 (±4.15) | 0.09 |
| Treatments | 5 (13.89%) | 4 (7.02%) | 0.27 |
| Remdesivir trial* | 12 (33.33%) | 28 (42.42%) | 0.36 |
| Sarilumab trial† | 0 | 12 (18.18%) | 0.006 |
| Anakinra | 5 (13.89%%) | 1 (1.52%) | 0.011 |
| Tocilizumab | 1 (2.70%) | 0 | 0.18 |
| Etoposide | 11 (30.56%) | 8 (12.12%) | 0.02 |
| IVIG | 26 (72.22%) | 40 (60.61%) | 0.24 |
| Pulse steroids | 6 (16.67%) | 16 (24.24%) | 0.37 |
| Hydroxychloroquine | 12 (41.38%) | 22 (61.1%) | 0.30 |
| Azithromycin | 24 (64.86%) | 15 (22.39%) | 0.16 |
| Antibiotics |
*Smoking—current vs former/non-smokers. NCT04292899 and NCT04292899.
Abs Lymph Ct, absolute lymphocyte count; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea Nitrogen; CKD, chronic kidney disease; CRP, C reactive protein; Dx, diagnosis; HD, haemodialysis; IL-6, interleukin 6; LDH, lactate dehydrogenase.